$AITX to Host Investor Town Hall and RAD Technology

New Post Public Reply Private Reply Replies (1) Message Board
Lee Adams budfoxfun #25689
140
$AITX to Host Investor Town Hall and RAD Technology Reveal

November 3rd Event to Showcase Solutions from AITX Subsidiaries RAD, RAD-M and RAD-G


Detroit, Michigan, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Artificial Intelligence Technology Solutions, Inc., (OTCPK:AITX), today announced that it will host an Investor Town Hall and RAD Technology Reveal on Friday November 3, 2023. The event will be held at the Motor City Casino in Detroit, Michigan.

"I can't believe it's been nearly a year since we last opened our doors to the AITX community," said Steve Reinharz, CEO of AITX. "Since the REX is incredibly busy building solutions for our clients, we've decided to host the event off campus. The Motor City Casino is a great location to hold the event, and if our attendees are watchful, they may just spot a ROSA or two on the premises".

At the event, attendees can expect to see a live demonstration of RADDOG 3S, the purpose-built robot dog exclusively for the security services and #proptech industries. "What we previewed on FOX TV's 'Stars on Mars' was just a small tease of all that RADDOG 3S is capable of. You're going to want to be there, or tune in to the livestream," Reinharz added.

Those interested in attending the AITX Investor Town Hall and RAD Technology Reveal can register online at tinyurl.com/2xv94nbw. For those unable to attend the event in person, it will be livestreamed on AITX's YouTube channel www.youtube.com/aitxrad.

Additional details regarding the event will be released in the coming weeks. These may include specifics on the other technologies and solutions being demonstrated and ways for the attendees to get up close and personal with the solutions. Reinharz added, "Our beloved AITX community has come to expect big 'ah-ha' moments at these events. We're pulling out all the stops once again to make sure this is a home run."

AITX, through its subsidiary, Robotic Assistance Devices, Inc. (RAD), is redefining the $25 billion (US) security and guarding services industry through its broad lineup of innovative, AI-driven Solutions-as-a-Service business model. RAD solutions are specifically designed to provide cost savings to businesses of between 35%-80% when compared to the industry's existing and costly manned security guarding and monitoring model. RAD delivers this tremendous cost savings via a suite of stationary and mobile robotic solutions that complement, and at times, directly replace the need for human personnel in environments better suited for machines. All RAD technologies, AI-based analytics and software platforms are developed in-house.

About Artificial Intelligence Technology Solutions (AITX)

AITX is an innovator in the delivery of artificial intelligence-based solutions that empower organizations to gain new insight, solve complex challenges and fuel new business ideas. Through its next-generation robotic product offerings, AITX's RAD, RAD-M and RAD-G companies help organizations streamline operations, increase ROI, and strengthen business. AITX technology improves the simplicity and economics of patrolling and guard services and allows experienced personnel to focus on more strategic tasks. Customers augment the capabilities of existing staff and gain higher levels of situational awareness, all at drastically reduced cost. AITX solutions are well suited for use in multiple industries such as enterprises, government, transportation, critical infrastructure, education, and healthcare. To learn more, visit www.aitx.ai, www.radsecurity.com,www.stevereinharz.com, www.radgroup.ai, www.raddog.ai, and www.radlightmyway.com, or follow Steve Reinharz on Twitter @SteveReinharz.

CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS

The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Artificial Intelligence Technology Solutions, Inc. (the "Company". This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company's future revenues, results of operations, or stock price.

###

Steve Reinharz

949-636-7060

@SteveReinharz
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 9

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 4

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 3

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 5

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 6

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 3

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 4

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading

Top 5 Most Recently Viewed Articles

Soleno Therapeutics Celebrates FDA Approval of VYKAT XR for PWS

Updated Category News Views 420

Soleno Therapeutics Announces FDA Approval for VYKAT XR Soleno Therapeutics, Inc. (NASDAQ: SLNO), a notable biopharmaceutical company, has made a significant announcement regarding the U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets. This new treatment targets hyperphagia in individuals aged four and older...

Continue Reading
aTyr Pharma Faces Legal Challenges: Investors Urged to Act

Updated Category News Views 173

aTyr Pharma's Legal Situation and Its Implications Recent developments surrounding aTyr Pharma, Inc. (NASDAQ: ATYR) have caught the attention of investors, particularly as the company faces significant legal challenges. The situation arose from a steep decline in share value triggered by disappointing results from a key clinical trial. This decline, marked by an...

Continue Reading
Primo Brands Boosts Share Repurchase Program by $50 Million

Updated Category News Views 145

Primo Brands Boosts Share Repurchase Program Primo Brands Corporation (NYSE: PRMB) is excited to announce a significant increase in its share repurchase program. This decision, made by the Board of Directors, involves raising the repurchase authorization by $50 million, bringing the total program authorization to an impressive $300 million. This enhancement in the share...

Continue Reading
GOTRAX Partners with RSMG Select to Inspire Youth Movement

Updated Category News Views 83

GOTRAX Teams Up with RSMG Select for Youth Development GOTRAX has embarked on an inspiring journey through its partnership with RSMG Select, aimed at nurturing not just young athletes but the community at large. The collaboration has transformed the experience for youth participating in futsal, allowing for significant growth and empowerment beyond the typical sports...

Continue Reading
Zenas BioPharma Celebrates Major Milestones in Q3 2025

Updated Category News Views 245

Zenas BioPharma Celebrates Major Milestones in Q3 2025 - Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end. - Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS). - Secured development and commercialization rights for three...

Continue Reading